BioSpace News Archive

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (“BioHarvest” or the “Company”) has announced a collaboration with the International Neurorehabilitation Institute (INI) (https://inirehab.com/) in Lutherville, Maryland to perform a clinical trial to assess the capacity of its RGC composition to promote eye health.

Canada Diagnostic Centres, a leading provider of medical imaging services, announces the strategic acquisitions of both Guardian Radiology and The Ultrasound Centre.

Select Medical announced a joint venture agreement with AtlantiCare to own and manage operations of a new inpatient rehabilitation hospital and 13 outpatient physical therapy centers throughout the southeastern region of New Jersey.

The advent of immunotherapy has set a development foundation for modern cancer therapies, allowing emergence of novel modalities and targets shaping the future landscape for cancer treatment.

Cure Alzheimer’s Fund, a nonprofit dedicated to funding the most promising research to prevent, slow or reverse Alzheimer’s disease, is pleased to announce the appointment of Drs. John S. Lazo and Patrick C. May to its Research Strategy Council.

electroCore, Inc., a commercial-stage bioelectronic medicine and wellness company, announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-15.

Eurofins Discovery, the leading provider of products and services to the drug discovery industry, announced its collaboration with Invasight, a Switzerland-based biotech developing cancer therapies.

Bio North Texas launched a video promoting growth and strength in the North Texas biomedical innovation ecosystem.

The FDA has approved the first Non-Covalent (Reversible) BTK (Bruton Tyrosine Kinase) inhibitor for the treatment of Relapsed or Refractory Mantle Cell Lymphoma in adult patients, based on clinical studies conducted with participation by Florida Cancer Specialists & Research Institute.

Eluminex Biosciences today announced the completion of clinical enrollment in Part A (N=5) of a two-part pivotal study (CLARITY) evaluating a novel EB-301 biosynthetic cornea being conducted in China.